CORDIS Project
Funding breakdown and partner intelligence are Premium
Sign in and upgrade to Premium for EU contribution totals, consortium analytics, OpenAlex research context, and AI summaries. · 0 consortium intelligence fields visible of 1
Start free • Cancel anytime • 14-day refund guarantee
VOLABIOS aims to improve the diagnosis and management of schizophrenia by validating volatile organic compounds as non-invasive biomarkers. The project involves extensive clinical studies and integrates various biological analyses to enhance early detection.
Schizophrenia (SZ) impacts around 1% of the global population, posing diagnostic challenges that lead to a misdiagnosis rate of 23-40%.
The need for reliable biomarkers is crucial to improve early detection and treatment outcomes. VOLABIOS aims to revolutionize SZ management by harnessing innovative real-time and portable spectrograph technology to validate volatile organic compounds (VOCs) as non-invasive and cost-effective biomarkers detectable during the early stages of the disease.
This enta…
Partner organizations (coordinator is shown above), with normalized type and CORDIS activity type. Guests see up to 4 partners.
Israel, Haifa
Type: Company (for-profit)
Activity type: Private for-profit entities (excluding Higher or Secondary Education Establishments)
SME: No
EXUS SOFTWARESINGLE MEMBER LIMITED LIABILITY COMPANY
Greece, ATHENS
Type: SME
Activity type: Private for-profit entities (excluding Higher or Secondary Education Establishments)
SME: Yes
Spain, Sevilla
Type: Public body
Activity type: Public bodies (excluding Research Organisations and Secondary or Higher Education Establishments)
SME: No
Similar projects, consortium collaboration history, frequent partners, and OpenAlex research context.
Guests see up to 5 EuroSciVoc fields.
Guests see up to 5 topics.
Guests see up to 5 sectors.
Guests see up to 5 keywords.
